Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography by Zhu, Xiao-Dong et al.
RESEARCH ARTICLE Open Access
Antiangiogenic effects of pazopanib in xenograft
hepatocellular carcinoma models: evaluation by
quantitative contrast-enhanced ultrasonography
Xiao-Dong Zhu
1†, Ju-Bo Zhang
1†, Pei-Li Fan
2†, Yu-Quan Xiong
1, Peng-Yuan Zhuang
1, Wei Zhang
1, Hua-Xiang Xu
1,
Dong-Mei Gao
1, Ling-Qun Kong
1, Lu Wang
1, Wei-Zhong Wu
1, Zhao-You Tang
1, Hong Ding
2*, Hui-Chuan Sun
1*
Abstract
Background: Antiangiogenesis is a promising therapy for advanced hepatocellular carcinoma (HCC), but the
effects are difficult to be evaluated. Pazopanib (GW786034B) is a pan-vascular endothelial growth factor receptor
inhibitor, the antitumor effects or antiangiogenic effects haven’t been investigated in HCC.
Methods: In vitro direct effects of pazopanib on human HCC cell lines and endothelial cells were evaluated. In
vivo antitumor effects were evaluated in three xenograft nude mice models. In the subcutaneous HCCLM3 model,
intratumoral blood perfusion was detected by contrast-enhanced ultrasonography (CEUS), and serial quantitative
parameters were profiled from the time-intensity curves of ultrasonograms.
Results: In vitro proliferation of various HCC cell lines were not inhibited by pazopanib. Pazopanib inhibited
migration and invasion and induced apoptosis significantly in two HCC cell lines, HCCLM3 and PLC/PRF/5.
Proliferation, migration, and tubule formation of human umbilical vein endothelial cells were inhibited by
pazopanib in a dose-dependent manner. In vivo tumor growth was significantly inhibited by pazopanib in
HCCLM3, HepG2, and PLC/PRF/5 xenograft models. Various intratumoral perfusion parameters changed over time,
and the signal intensity was significantly impaired in the treated tumors before the treatment efficacy on tumor
size could be observed. Mean transit time of the contrast media in hotspot areas of the tumors was reversely
correlated with intratumoral microvessel density.
Conclusions: Antitumor effects of pazopanib in HCC xenografts may owe to its antiangiogenic effects, and the in
vivo antiangiogenic effects could be evaluated by quantitative CEUS.
Background
Hepatocellular carcinoma (HCC), one of the most vas-
cularized solid cancers [1], is the sixth most common
cancer and the third most common cause of death
from cancer worldwide [2]. This disease is usually
diagnosed at an advanced stage, and therefore it pre-
sents a dismal prognosis, owing to the lack of effective
systemic treatment options and the underlying liver
disease [3]. Overall survival may be improved after the
clinical application of sorafenib or other molecular tar-
geting agents [4,5]. Tumor angiogenesis plays a critical
role in the development and progression of HCC,
which suggests that antiangiogenic therapy is effective
in inhibiting tumor progression. The role of vascular
endothelial growth factor (VEGF) and VEGF receptors
(VEGFR) in the angiogenesis and progression of HCC
has been well documented [6-8], providing a rationale
for investigating VEGF or VEGFR-targeted therapies.
Several clinical studies support antiangiogenic thera-
pies in HCC, including bevacizumab [9,10], sorafenib
[5], and others [11]. With the advent of these antian-
giogenic therapies, there is increased interest in deter-
mining the clinical effects of these agents. Given the
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the classical definition of tumor response, tumor size
reduction, may need to be revised. Thus there is a
need for better understanding of how imaging methods
may be utilized to assess the physiologic status of the
tumor neovasculature and the activity of these agents
in clinical use.
The change of intratumoral microvessel density
(MVD) has been widely used to detect the response of
antiangiogenic therapy in animal models, but its pre-
dictive value of treatment response was questioned in
clinical settings because of some limitations [12,13].
For example, repeated biopsy to facilitate histological
examination is usually impossible in clinical settings,
especially in patients with HCC, which is often asso-
ciated with coagulation dysfunction or ascites. There-
fore noninvasive or minimally invasive methods is
needed to monitor the biological response. Tumor per-
fusion measured by imaging methods, such as dynamic
contrast-enhanced computed tomography (DCE-CT)
and dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI), have been reported [14-17]. With
the use of microbubble contrast agents, contrast-
enhanced ultrasonography (CEUS) could also provide a
sensitive method to detect tumor perfusion [18-21].
With more convenient application, the diagnostic value
of CEUS is similar to DCE-CT and DCE-MRI [22,23].
CEUS is nowadays widely used in diagnosis [24] or in
predicting the treatment efficacy of local therapies
[25-27] in HCC, but assessment of the efficacy of the
targeted therapies was scarcely reported. CEUS, com-
bined with a computerized imaging analysis system,
can depict the perfusion with serial parameters to
quantitative blood perfusion in multiple characteristics
by analysing the time-intensity curve (TIC) obtained
from regions of interest (ROI). In two previous studies
assessing angiogenesis [20] or efficacy of antiangio-
genic therapy [19] with CEUS, the correlation between
MVD and parameters of CEUS was controversial
[19,20], and only a few parameters were quantified,
while the dynamic changes of the parameters during
antiangiogenic therapy were not well observed.
In this study, the antitumor effect of pazopanib
(GW786034B; GlaxoSmithKline, Collegeville, PA), a
small-molecule tyrosine kinase inhibitor of VEGFRs, pla-
telet-derived growth factor receptors, and c-Kit tyrosine
kinases [28], were evaluated in 3 human HCC xenograft
models. By analysis of dynamic images of CEUS, intratu-
moral blood perfusion was profiled by serial quantitative
parameters, and biologic implications of these para-
meters were evaluated. Some CEUS parameters may be
used as surrogate markers of MVD or used to quantita-
tively measure the intratumoral perfusion changes in the
context of antiangiogenic treatment.
Methods
Cell lines and cell culture
Human HCC cell lines with high metastatic capacity
(HCCLM3, MHCC97-H, and MHCC97-L, which were
established by our institute [29]) or low metastatic capa-
city (SMCC7721, HepG2, and PLC/PRF/5) from ATCC
cell bank were grown as a monolayer culture in Dulbec-
co’s modified Eagle’s medium or RPMI-1640 supple-
mented with 10% fetal calf serum, 100 U/mL penicillin,
and 50 μg/mL streptomycin. Human umbilical vein
endothelial cells (HUVEC, ScienCell Research Labora-
tories, San Diego, CA) and tumor-derived endothelial
cells (TEC), established as previously described [30],
were maintained on an endothelial cell medium (Scien-
Cell Research Laboratories), and cells at passage 3 or 4
were chosen for experiments. All these cells were cul-
tured at 37°C in a 5% CO2, 95% air environment in
humidified incubators. Pazopanib, provided by GlaxoS-
mithKline in a purified powder, were reconstituted in
dimethyl sulphoxide (DMSO) at a concentration of 300
μg/mL before use.
Proliferation assay and Apoptosis assays
CellTiter-Glo
® luminescent cell viability assay (Promega,
Madison, WI) was used to test the proliferation of cells
in response to different concentrations of pazopanib,
following the manufacturer’s instructions. Briefly, 2 ×
10
3 cells, HUVEC, TEC, SMCC7721, HCCLM3,
MHCC97-H, MHCC97-L, HepG2, and PLC/PRF/5 were
plated in the 96-well opaque-walled multiwell plates in
culture medium. Control wells containing medium with-
out cells were set to obtain a value for background
luminescence. After adherent culture, pazopanib (final
concentrations of 0, 1, 2, 5, 10, and 20 μg/mL) was
added to each well and incubated for 72 h, and 80 μL
CellTiter-Glo reagent was then added in each well.
After being mixed and incubated at room temperature
for 10 min, the luminescence of each well was recorded.
HCCLM3, HepG2, and PLC/PRF/5 cells which were cul-
tured in serum-free DMEM with 25 μg/mL pazopanib
or vehicle for 6 h were collected and analysed for the
presence of apoptotic cells using Annexin V-FITC
Apoptosis Detection Kit (BD Pharmingen, San Jose, CA)
following the manufacturer’s instruction. Flow cytometry
analysis was performed using FACS Calibur cytometer
(R&D Systems, Minneapolis, MN). Replicate assays were
done.
Tumor cell migration and invasion assay
Transwell chamber inserts (Corning Inc, Corning, NY)
with filter membrane pore size of 8 μmw e r ec o a t e d
with 80 μL Matrigel (0.8 mg/mL, BD Bioscience,
Mountain View, CA). Tumor cells, HCCLM3, HepG2,
and PLC/PRF/5, at the concentration of 5 × 10
5/mL
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panib or vehicle at the upper chamber. DMEM contain-
ing 10% FBS was added to the lower compartment.
Seventy-two hours later, cells that migrated through the
permeable membrane were fixed in paraformaldehyde,
stained with Giemsa, and counted under an inverted
light microscope at 100× magnification. Each assay was
done at least in triplicate. Migration assay were applied
similarly without coating the upper chamber with Matri-
gel, and the cells migrated through the membrane were
counted at 48 h.
Wound-healing assay
HUVEC were seeded in 24-well plates and incubated for
12 h; the monolayer-adherent HUVEC were established.
A line was scratched by a sterilized pin to wipe off the
adherent cells in this line to create a wound. After being
washed with PBS, pazopanib was then added to the med-
ium (final concentrations of 0, 1, 4, 20, and 100 μg/mL)
and a control was set up with an equal concentration of
DMSO. Seven hours later, the migration of HUVEC was
assessed using an inverted light microscope at 50× mag-
nification; the distances HUVEC migrated in the 7 h
were measured.
In vitro angiogenesis assay (tubule formation assay)
In vitro formation of capillary-like structures was stu-
died on growth factor-reduced Matrigel (BD Bios-
ciences) diluted 1:1 on ice with cold endothelial cell
medium in a 96-well plate. 5 × 10
4 HUVEC were inocu-
lated on the surface of the Matrigel, after the adherent
culture under normoxic conditions was reached and pazo-
panib (final concentrations of 0, 10, 20, and 40 μg/mL)
was added. Tubule formation of HUVEC was assessed 3
and 6 h later under an inverted light microscope at
50× magnification.
Animals
Male BALB/c nu/nu mice (4-6 wk old) of around 20 g
(Shanghai Institute of Materia Medica, Chinese Acad-
emy of Sciences, Shanghai) were housed in laminar-flow
cabinets under specific pathogen-free conditions. The
mice were cared for and handled according to the U.S.
P u b l i cH e a l t hS e r v i c eP o l i c yo nH u m a n eC a r ea n dU s e
of Laboratory Animals. The experimental protocol was
approved by the Shanghai Medical Experimental Animal
Care Committee. Mice were inoculated subcutaneously
in the right dorsal part near the lower pole of right kid-
ney with 5 × 10
6 HCCLM3, which could induced high
incidence of lung metastasis when implanted either sub-
cutaneously or orthotopically in nude mice [29], or
PLC/PRF/5 cells with low metastatic capacity. Orthoto-
pic HepG2 xenograft model was established by implan-
tation of tumor blocks at the average volume of 1 mm
3.
Two weeks later, the xenograft model was established
which was confirmed by conventional ultrasound with a
high-frequency transducer; mice were then randomized
into a pazopanib-treated group and a control group in a
size-matched manner. Pazopanib was suspended in 0.5%
hydroxypropylmethyl cellulose (Sigma-Aldrich, St. Louis,
MO) and 0.1% Tween-80 (Sigma-Aldrich) in water as a
vehicle (pH 1.3-1.5) and was given 40 mg/kg daily by
oral gavage. The control group received the vehicle
alone at the same schedule and route of administration.
Tumor burden was measured every week by ultrasound
when CEUS was applied for subcutaneous HCCLM3
tumor model. Animals were sacrificed to obtain the
tumors for histological study at the indicated time
points. To evaluate the therapeutic effects of pazopanib,
a pilot study was performed at a higher dosage (60 mg/
kg/d) in HCCLM3 xenograft model in advance (Addi-
tional file 1, Figure S1).
CEUS protocols
The sonography investigators were blinded in regard to
the groups. Animals of the subcutaneous HCCLM3
model were imaged on days 0, 7, 14, and 21 after treat-
ment. Conventional ultrasound and harmonic CEUS
were performed using a commercially available ultra-
sound system iU22 (Philips, Bothell, WA). A L17-9 lin-
e a ra r r a yt r a n s d u c e rw a su s e df o rt h ec o n f i r m a t i o no f
planted tumor and the measurement of tumor volume,
and a L9-3 linear array wideband transducer combined
with Pulse Inversion Harmonic technique was used for
CEUS study. Imaging settings, including mechanical
index (0.1), frame rate (18 Hz), compress (36 dB), gain,
focus, depth, and depth gain compensation line, were
established after optimization at the beginning and were
fixed in this study. Mice were anesthetized with sodium
pentobarbital (50 mg/kg intraperitoneally) and placed in
the prone position on a polystyrene plastic pad. The
centrifuged ultrasound coupling gel was filled to the
thickness of 5 mm for maintenance between the surface
of the transducer and the skin of the tumor. To avoid
the potential functional effects on the endothelial cells
of the antiangiogenic agents [12], CEUS was performed
at least 8 h (range, 8 - 12) after the daily administration
of pazopanib. At each imaging session, tumor volumes
were assessed by conventional B-mode imaging and cal-
culated as 0.52 × length × width × depth. During the
contrast session, the longitudinal scan was chosen to
display the largest dimension of the tumor and the right
kidney. The transducer was then held in this position
through the examination. Animals received a bolus
injection of 0.02 mL (45 μg/mL) microbubble contrast
agent (SonoVue, Bracco SpA, Milan, Italy) within 1-2 s.
The contrast medium consists of a suspension of sul-
phurhexafluoride microbubbles surrounded by a thin
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microbubbles to withstand several passes through the
pulmonary capillaries. Each bolus injection of SonoVue
was through a 27-gauge needle mounted to the tail vein,
followed by a 0.2 mL saline flush. To control the quality
of imaging, the enhancement in the imaging plane of
the cortex of the ipsilateral kidney was also observed
simultaneously. All the images were recorded in digital
cine clips from the beginning of injection; recordings
lasted for at least 2 min and were transferred in Digital
Imaging and Communications in Medicine format to a
PC for further analysis.
Imaging data analysis
Dynamic digital data sequences of CEUS were analysed
off-line with the software SW-UCS (Shenwei Imaging
Technology Company, Shanghai, China) by the sonogra-
phy investigators. After browsing the dynamic perfusion
of the whole tumor frame by frame, two ROIs were
placed to generate two initial time-intensity curves
(TICs) presenting dynamic changes of signal intensity in
the selected region. One ROI was placed to cover the
tumor area as a whole, and the other one was located in
the most enhanced area in the tumor on CEUS, which
was referred as a “hotspot” area. The shape of ROI was
a circle drawn manually and the area of ROI approxi-
mately ranged from 5 mm
2 to 800 mm
2.B yt r a c k i n g
every frame of contrast-enhanced images, the average
intensity and initial TIC of each ROI were obtained.
The initial TIC of each ROI was analysed and fitted
with a least mean square method adaptable to bolus
injection [31,32] and a series of quantitative parameters
were calculated automatically with a mathematical func-
tion It a a e
e
at
at t () () =+
+
−
−− 01
2
30 1
, which was adaptable
to the kinetics of bolus injection as reported by Postert,
et al. [32] Serial quantitative parameters of each ROI
achieved from fitted TIC solved at every pixel in each
ROI were calculated automatically (Additional file 1,
Figure S2). The obtained TIC typically presented a base-
line phase prior to the contrast and then a rapid
increase in the signal intensity to a peak level followed
by a slow washout phase. Quantitative parameters
derived from the fitted curve (Table 1), including
increased signal intensity from baseline (ISI), and rate of
signal increase (RSI) in the rising period, rate of washout
of 50% contrast material (RWO), mean transit time
(MTT) of the contrast material, area under curve
(AUC), and blood flow coefficient (BF; AUC/MTT × 2).
These parameters could be classified into two types-
volume related parameters, including AUC, ISI, and BF,
and velocity related parameters, including RSI, RWO,
and MTT. The volume related parameters were used to
define the volume of blood perfusion in the ROI, while
the velocity related parameters were used to define
change of blood flow within a unit time in the area of
interest. To reduce the variability among different sub-
jects, which was probably due to the potential variation
in the amounts of contrast entering the circulation, the
volume-related parameters were standardized by divid-
ing the corresponding parameters detected in the ipsilat-
eral kidney and were presented as ratios.
Histological study (necrosis, proliferation, hypoxia, and
microvessel and pericyte density) in HCCLM3 models
Thirty minutes after intraperitoneal injection with 60
mg/kg pimonidazole hydrochloride (Chemicon Interna-
tional, Temecula, CA) [33,34], animals were anesthetized
and infused via cardiac puncture with warm PBS fol-
lowed by 4% paraformaldehyde/PBS. Tumors were dis-
sected with the mark of scanning slice and direction on
CEUS and fixed with 4% formaldehyde. The specimens
were then dehydrated, embedded in paraffin, and sec-
tioned at 6 μm. Sections were stained with H&E or were
subjected to immunohistochemistry study, with primary
antibodies against pimonidazole hydrochloride for
hypoxia, CD31 (Abcam, Cambridge, MA) for tumor
microvessels, and Ki-67 (Dako, Carpinteria, CA) for cell
proliferation. Negative controls were treated identically
but with the primary antibodies omitted. The compo-
nents of the Envision-Plus detection system (EnVision/
HRP/Mo, Dako) were then applied. Reaction products
were visualized by incubation with 3,3-diaminobenzi-
dine. The necrosis index or hypoxia index was calcu-
lated as the ratio of necrotic area or pimonidazole
stained area to the total area in the whole transverse
section. MVD was determined by scanning stained
tumor sections at low power, and areas of greatest
CD31 positive density were chosen for analysis. The
ratio of the positively stained cells to the total area
of the field at the magnification of 200× was counted
as MVD using Leica QWin Plus v3 software (Leica
Microsystems Imaging Solutions, Cambridge, UK), as
described previously [10]. The proliferation rate was
counted as the proportion of the Ki-67-stained nuclei to
the number of total nuclei in the field. MVD and prolif-
eration rate were evaluated in at least 5 randomized
chosen fields without necrosis within each tumor. Intra-
tumoral pericyte density was evaluated in frozen sec-
tions by immunofluorescence staining with primary
antibody against mouse a-smooth muscle actin (a-
SMA; Abcam) and Cy5-conjugated anti-rabbit IgG
(Jackson ImmunoResearch, West Grove, PA) was used
as the second antibody. a-SMA-positive pericytes were
counted in the graphics acquired at the magnification of
100× using an inverted fluorescence microscope. a-
SMA-positive tumor encapsulation was used as a
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when processing with Leica QWin Plus v3 software.
Statistical Analysis
Statistical comparisons were performed using the Stu-
dent’s t test when data were normally distributed or
using the nonparametric analyses of Spearman and
Mann-Whitney when data were not normally distribu-
ted. One-way analysis of variance (ANOVA) was used to
study the temporal variations of the CEUS parameters
during tumor progression or during pazopanib treat-
ment, and the Least Significant Difference test was used
to compare between two time points, when necessary.
Spearman’s rank order correlation was used to investi-
gate the relationships between tumor perfusion and his-
tological features. Two-sided P values less than 0.05
were considered statistically significant.
Results
In vitro Studies
The proliferation and survival of the tested human
hepatoma cell lines were slightly affected by pazopanib
at concentrations between 1 and 20 μg/mL, whereas
the proliferation of HUVEC and TEC was inhibited in
a dose-dependent manner (Figure 1A), with an IC50
ranging between 5 and 15 μg/mL in 72 h. Pazopanib
could induce moderate apoptosis of HCCLM3 and
PLC/PRF/5 at the concentration of 25 μg/mL, whereas
the apoptosis of HepG2 cells was also not significantly
enhanced by pazopanib (Figure 1B). Migration through
the filter membrane of the Transwell chamber was sig-
nificantly inhibited by pazopanib at the concentration
of 25 μg/mL in HCCLM3, PLC/PRF/5, and HepG2
cells. The invasion through Matrigel could be also
inhibited by pazopanib in these hepatoma cells except
in HepG2 cells, which could not invade through the
Matrigel even when treated with the vehicle only
(Figure 1C). The migration of HUVEC was inhibited
by pazopanib in a dose-dependent manner as detected
by the wound-healing assay (Figure 1D). When the
concentration reached 20 μg/mL, the migration of the
HUVEC was reduced by 30% compared with the vehi-
cle-treated cells. Overwhelming cell death could be
observed at the concentration of 100 μg/mL, and the
migration was difficult to be evaluated. Tubule forma-
tion of HUVEC was also inhibited in a dose-dependent
manner by incubation with pazopanib for 3 or 6 h. No
tube was formed when the concentration reached
20 μg/mL or higher (Figure 1E).
Pazopanib inhibits xenograft tumor growth
A pilot study showed that pazopanib (at a dose of 60
mg/kg daily) significantly inhibited HCCLM3 growth
and prolonged the survival of tumor-bearing mice
(Additional file 1, Figure S1). To catch the perfusion
changes in the course of treatment by weekly applied
CEUS, instead of the changes merely at the end of treat-
m e n t ,al o w e rd o s a g eo f4 0m g / k g / dw a su s e di nt h i s
study. After treated with pazopanib for 3 wk, the tumor
growth of HCCLM3 was significantly delayed as com-
pared with the control (0.43 ± 0.17 cm
3 versus 0.93 ±
0.44 cm
3, n = 7 and 5 for each group, P = 0.037; Figure
2A). It is also noticed that the difference in tumor size
(based on the 3 dimensions detected by ultrasonography
in live animals) between the two groups was not statisti-
cally significant at the end of 1 wk or 2 wk after the
initiation of the treatment (0.16 ± 0.08 versus 0.20 ±
0.13 cm
3, P = 0.364; 0.35 ± 0.21 versus 0.45 ± 0.23 cm
3,
P = 0.673; respectively). Tumor growth were also signifi-
cantly inhibited by 4-week pazopanib treatment in two
other xenograft hepatoma models, including orthotopic
HepG2 model (0.64 ± 0.16 cm
3 in control [n = 6] versus
0.16 ± 0.05 cm
3 in pazopanib group [n = 5], P =0 . 0 3 1 )
and subcutaneous implanted PLC/PRF/5 model (0.86 ±
0.32 cm
3 in control versus 0.48 ± 0.11 cm
3 in pazopanib
group, n = 7 for each group, P = 0.012).
Table 1 Terms used to portray the perfusion by contrast-enhanced ultrasonography
Acronym Parameter Notes
TIC time-intensity curve A curve to describe the signal intensity of contrast media in a region of interest changes over time
when a series of ultrasonograms are analysed by specific software offline
ROI region of interest A circle drawn in the interested region for generating the time-intensity curve. In this study, one ROI
took the tumor region as a whole, the other one, “hotspot”, was located in the highest enhanced area
on contrast-enhanced ultrasonography, which were determined by the two sonography investigators
ISI increased signal intensity The difference between baseline to the maximum increase in signal intensity in a region of interest
RSI rate of signal increase The rate of signal enhancement from baseline to initial peak in a region of interest
RWO rate of washout of 50% of
contrast material
The rate of signal intensity reduced to 50% of initial peak of contrast material in a region of interest
MTT mean transit time Average persistence of a contrast material in a region of interest
AUC area under the curve Integral calculus of the area under time-intensity curve, which reflects the total perfusion of a region of
interest
BF blood flow coefficient BF = AUC/MTT/2
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At the end of the third week, the mean MVD in the
treated tumors was significantly lower than that in the
control (3.1% versus 5.8%, P =0 . 0 0 8 ;F i g u r e2 B ) .
Endothelial cells formed dilated, disorganized, and tortu-
ous networks in the control, while looking straight and
regular in pattern in the pazopanib group (Figure 2B).
Whereas the intratumoral a-SMA-positive pericytes
density in the pazopanib treated tumors was signifi-
cantly higher than those in control (3.5% ± 0.8% versus
1.4% ± 0.6%, P = 0.001; Figure 2C). The necrosis and
hypoxia indexes, evidenced by H&E staining and pimo-
nidazole immunostaining, were not significantly changed
(64% versus 67%, P = 0.729, and 34% versus 35%, P =
0.857, respectively). The difference between the prolif-
eration rates of the tumor cells in the pazopanib group
Figure 1 In vitro effects of pazopanib on hepatoma cells and endothelial cells. The effects of pazopanib on the in vitro proliferation of
various human liver cancer cells, human umbilical vein endothelial cells (HUVEC) and tumor-derived endothelial cells (TEC) at various
concentrations (A), and on the apoptosis (B) and migration and invasion of 3 liver cell lines (C) at the concentration of 25 μg/mL. Tubule
formation (D) and migration of HUVEC (E) were inhibited by pazopanib in a dose-dependent manner. Each experiment was repeated at least
three times. Results of a representative study. Bars, SD; asterisks, P < 0.05 as compared with control.
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28.1%, P = 0.188). It should be noted that the tumor
necrosis index correlated well with the tumor size (r =
0.670, P < 0.001). The tumor in the pazopanib-group was
smaller in size but have similar necrosis index in compare
with the control group, this may be resulted in the poten-
tial pro-necrotic effects of pazopanib. Although a signifi-
cant correlation was also found between the hypoxia index
and tumor size (r = 0.719, P < 0.001), the standardized
hypoxia index in the treated tumors was higher than in
the untreated groups, but the difference was not signifi-
cant (0.8 × 10
-3/mm
3 versus 0.4 × 10
-3/mm
3, P = 0.092).
Correlations between tumor perfusion and histological
features
Putting the two cohorts (the treated and untreated
tumors) together, correlations between the histological
features (e.g., necrosis and hypoxia index) obtained in
the cross sections of the tumors and the parameters
obtained by CEUS were evaluated. Two ROI were
selected from each tumor, when the sonography was
analysed. One ROI was placed to cover the entire tumor
section as a whole, the other was located in the most
enhanced area in CEUS, which was referred as a “hot-
spot” area. Terms used to portray the perfusion by
Figure 2 In vivo effects of pazopanib on the HCCLM3 xenograft model. Pazopanib inhibited in vivo tumor growth and intratumoral
angiogenesis in a subcutaneously implanted HCCLM3 model. Three weeks after the treatment, tumor growth was significantly delayed as
compared with the control (A). Microvessels evidenced by anti-CD31 immunostaining were lower in the pazopanib-treated tumors than the
tumors treated with vehicle only (B). Endothelial cells formed dilated, disorganized, and tortuous networks in the control, while looking straight
and regular in pattern in the pazopanib-treated tumors (B). The density of alpha-smooth muscular actin (a-SMA)-positive pericytes were
increased by pazopanib treatment (C). The intratumoral microvessel density reversely correlated with the mean transit time of the contrast
flowing through the xenograft tumors detected in the hotspot areas by contrast-enhanced ultrasonography (D). Bars, SD.
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introductions were shown in Table 1.
As shown in Table 2, the necrosis and hypoxia
indexes were correlated with some of the velocity-
related parameters obtained from the whole tumor (RSI
and RWO) of entire tumor (P <0 . 0 5 ) .N os i g n i f i c a n t
correlation was found between volume-related para-
meters except ISI, obtained from the entire tumor area
and the necrosis index. No significant correlation was
found between MVD and all the parameters of CEUS in
the entire tumor (Table 1). The correlations between
the CEUS parameters from ROIs in the hotspot area
and the histological features obtained from non-necrotic
areas were evaluated as well (Additional file 1, Table
S1). MVD was reversely correlated with MTT measured
in the hotspot area (r = -0.661, P =0 . 0 0 1 ;F i g u r e2 D )i n
the two cohorts (including the treated and untreated
tumors, n = 12 in total). And this correlation was true
in the treated group (r = -0.556, P =0 . 0 3 9 ,n=7 )b u t
not in the control (r = -0.367, P = 0.332, n = 5). No sta-
tistically significant correlation was found between other
histological features (necrosis and hypoxia indexes) or
tumor size and all perfusion parameters detected in the
hotspot area, except a borderline significant correlation
between the necrosis index and BF detected in the hot-
spot area (P = 0.043; Additional file 1, Table S1).
Figure 3A showed two typical sonograms and the
TICs obtained from the kidney and entire tumor in the
mice from the treated group and the control group at
the end of the third week of the intervention, when
intratumoral blood perfusion was depressed in the trea-
ted mice, whereas the blood perfusion of the ipsilateral
kidney was slightly affected by pazopanib treatment
(Additional file 1, Table S2). Figure 3B presented the
perfusion changes of entire tumors in treated and con-
trol groups over time. Compared with the control, the
volume-related parameters (ISI, AUC, and BF) of the
entire tumor in treated tumors were significantly
increased at the end of the first week. But at the end of
the second week, when the tumor of the treated group
was slightly smaller than that of the control (Figure 3B),
all these parameters decreased, among which ISI was
significantly lowered (Figure 3B). At the end of the third
week, the tumor growth was significantly retarded in the
treated group and all these parameters were significantly
lowered in the pazopanib treated group (Figure 3B). On
the other hand, the velocity-related parameters (RSI,
RWO and MTT) in treated group changed gradually
and were significant at the end of third week (Additional
file 1, Table S3), especially the parameter of MTT,
which was significantly prolonged at the end of the
third week in the treated tumors (Figure 3B). These
results indicated that 3-wk pazopanib treatment could
lower the peak and the total perfusion of the tumor and
could prolong MTT of the contrast material flowing
through the tumor.
Discussion
In this study, we demonstrated the antiangiogenic effects
of pazopanib in several human HCC xenograft models,
which can be continuously and noninvasively assessed
by quantitative CEUS. Oral administration of pazopanib
at doses ranging from 10 to 100 mg/kg daily was pre-
viously shown to inhibit tumor growth in several human
tumor xenograft models [28,35]. The effect of pazopanib
on HCC, one of the most vascularized tumors, has not
been reported before. Daily treatment with pazopanib at
a dose of 40 mg/kg can effectively inhibit tumor growth
of 3 different human HCC xenograft models and pro-
long the life span of tumor-bearing nude mice, which
may attribute to the antiangiogenic effects of pazopanib.
It remain controversy that tumor cells or endothelial
cells, which cell type is main target of the tyrosine
kinase inhibitors. In this study, direct anti-proliferation
effect of pazopanib on hepatoma cells was not signifi-
cant either in vitro or in vivo. Although in vitro pazopa-
nib treatment could induce cell apoptosis and inhibit
invasion and migration features in some tumor cells, the
concentration of pazopanib is relatively high. To the
contrary, we found pazopanib could inhibit the prolif-
eration, migration, and tubule formation of HUVEC in
vitro and could reduce the intratumoral MVD in vivo.
So, the in vivo antitumor effects of pazopanib may be
indirect and may attribute to its antiangiogenic effects,
at least at the dosage of 40 mg/kg/d. Similar indirect
antitumor effects were reported by Kumar et al. [28] in
several other tumor models. Podar et al. [35] found that
pazopanib can block multiple myeloma cell growth and
survival in vitro. It may therefore be speculated that
direct anti-proliferation effects of pazopanib on tumor
cells may vary among cell lines.
Using a mathematic model to describe the TIC may
reduce the subjectivity of ultrasonography examinations.
Table 2 The correlations between the perfusion
parameters measured by contrast-enhanced
ultrasonography in the entire transverse tumor area and
histological features (n = 12)
Velocity-related
parameters
Volume-related
parameters
RWO RSI MTT ISI AUC BF
Necrosis index r -0.423 -0.656 0.139 -0.482 0.156 0.096
P 0.028 0.000 0.491 0.011 0.436 0.634
Hypoxia index r -0.470 -0.656 0.08 -0.332 0.269 0.212
P 0.024 0.001 0.72 0.122 0.215 0.330
Microvessel density r -0.212 0.002 -0.331 0.154 0.318 0.323
P 0.287 0.990 0.092 0.444 0.106 0.100
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could reflect the changes of tumor perfusion from differ-
ent aspects (Table 1), from which ISI stood out. When
the efficacy of pazopanib treatment was not proved by
tumor size at the end of the second week (Figure 2A), the
intratumoral peak perfusion (ISI) detected in the whole
tumor started to drop and remained lower afterward, as
compared with the control (Figure 3B). Meanwhile, the
present study also showed ISI reversely correlated with
tumor necrotic area, which was also increased in the trea-
ted tumor compared with the untreated tumor. This indi-
cates that the therapeutic response of pazopanib could be
sensitively detected by CEUS before a significant change
in tumor size, and thus CEUS may possibly meet the
demand for a novel method to define the biological
response to targeted therapy, which usually did not
reduce tumor size and therefore was not appropriate to
be judged in traditional ways. The Choi criteria, which
evaluated intratumoral necrosis by CT, has been
proposed recently [36]. In the present study, several para-
meters, including ISI obtained from the entire tumor,
were found to be significantly correlated with the necro-
sis index. The necrotic tissue without perfusion reduced
the average level of perfusion detected in the entire
tumor, and therefore ISI obtained from the whole tumor
reflects the mean level of the intratumoral peak perfusion
and is affected by the necrosis index. ISI may be used as
a comparable parameter in the Choi criteria in CEUS set-
tings. However, ISI also reflects tumor perfusion in the
nonnecrotic area, and seems better to compare with the
evaluation of the necrosis area alone. The hypothesis of
transient “normalizing tumor vasculature” following anti-
angiogenic therapy [37], whereby blood perfusion within
an individual vessel, demonstrated as ISI, AUC, and BF
in CEUS, may increase at the end of the first week
(Figure 3B).
Another parameter, MTT, obtained from the ROI
within the hotspot areas, was also highlighted.
Figure 3 Intratumoral blood perfusion detected by quantitative contrast-enhanced ultrasonography in pazopanib-treated HCCLM3
xenograft model. Panel A shows typical images of the contrast-enhanced ultrasonography (CEUS) in subcutaneous tumor (T) and ipsilateral
kidney (K) from the control (ctrl) and pazopanib-treated mice (pazo) 3 wk after the initiation of the treatment (left panels). ROIs were selected in
the tumor ("T,” yellow lines) and ipsilateral kidney ("K,” green lines), and the time-intensity curves (right panels) were then obtained in the two
regions of interest for further analyses. Tumor perfusion changed in a biphasic manner (panel B). The standardized volume-related parameters
detected by CEUS in the whole tumor changed over time. As compared to the control, an increase in signal intensity, the area under the curve,
and the blood flow coefficient increased 1 wk after the pazopanib treatment, but decreased afterward. Mean transit time of the contrast in the
tumor was also significantly prolonged at the end of the third week of the pazopanib treatment (A). Bars, SEM. Asterisks indicate P < 0.05.
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parameter found to be associated with the MVD mea-
sured in the viable area (Figure 2D). MTT acquired
from the entire tumor was also significantly prolonged
at the third week in this study (Figure 3B). Although
volume-related parameters (e.g., ISI) detected by CEUS
were found to be associated with MVD by previous stu-
dies [19,38,39], this correlation was not established in
this study, probably due to the small sample size and
different xenograft models. When microvessels in the
viable areas lowered after antiangiogenic therapy, and
then the flow-in and wash-out of the contrast was
restricted, as a result, MTT, a measurement of the aver-
age persistence of a contrast material in the circulation
[ 3 1 ] ,w a sp r o l o n g e d .T h eb i o l o g i cs i g n i f i c a n c eo fM T T
detected by CT perfusion scan was also revealed in a
recently published study; its baseline and change follow-
ing bevacizumab administration correlated with clinical
outcome, whereas the volume parameters (e.g., blood
flow and blood volume) did not [14]. When this correla-
tion was further tested in subgroups, we found that the
correlation was only established in the treated group.
The immature and inefficient neovasculature in the
tumor was more susceptible to the VEGF targeting ther-
apy and could be pruned by eliminating excess endothe-
lial cells, and the resulting vasculature is more
functional [37]. In this study, the findings that endothe-
lial cells looked straight and regular in pattern and that
density of a-SMA-positive pericytes was increased in
the tumors from pazopanib-treated mice indicated that
vessel normalization may be induced. And as an imaging
technology capable of measuring the functional perfu-
sion of contrast media, CEUS can only detect the func-
tional vessels but not the new angiogenic sprouts which
are always functionally invalid (not perfused by contrast
media). And the new angiogenic sprouts were pruned
by pazopanib and were dense in the control (Figure 2B).
Further histological studies are needed to define the
morphological and functional differences of the micro-
vessels between the two groups and explain why the
correlation between MTT and MVD could be found
only in the treated group. More recently, Palmowski
et al [40] evaluated large vessels and immature vessels
with high-frequency Doppler ultrasound technique
equipped by VisualSonics. Compared with the very
high-frequency transducer which is only eligible for
small animals, clinically available transducer used in the
study had relatively lower resolution for tumor vessels.
Although attempted, the CEUS system we used in this
study could detect the blood perfusion of the subcuta-
neous tumors but not of the intrahepatic ones, therefore
intratumoral perfusion of orthotopic HepG2 tumors
were not detected in this study. However, the quantita-
tive assessment of intratumoral perfusion is another
method to detect the functional vessels in tumors trea-
ted with antiangiogenesis. The present study provides a
rationale for testing the therapeutic effects of pazopanib
or other targeted agents with antiangiogenic effects in
patients with unresectable HCC.
This study has some limitations. First, although in vivo
effects of pazopanib were evaluated in 3 human HCC
nude mice models, other dosage and schedules of pazo-
panib or spontaneous model of liver cancer were not
tested in this study. Second, fine changes of tumor perfu-
sion may not be observed and only the subcutaneous
tumor models could be detected by this equipment due
to its relatively lower resolution and small tumor size. In
the clinical settings, the tumors are always of large size,
especially in the HCC patients with unresectable tumors
which are the indications of antiangiogenic therapy.
CEUS examination should be practical in these patients.
Third, the burst/replenishment kinetics which had some
advantages in minimizing the influence of cardiac output
[41] was not used in our study. We took the perfusion of
contrast in the ipsilateral kidney as a control for instead,
which may also reduce the influence of cardiac output.
Conclusions
In humans, pazopanib is currently being studied in more
than 40 clinical trials in various cancers, including a
phase I study to evaluate the safety, tolerability, and
optimal dosage in HCC patients. The findings of our
s t u d yp r o v i d ear a t i o n a l ef o rt e s t i n gt h et h e r a p e u t i c
effects of pazopanib in patients with unresectable HCC.
As CEUS has several advantages over DCE-MRI and
DCE-CT [42], the application of quantitative CEUS,
especially the two parameters ISI and MTT, deserves to
be further evaluated in comparative clinical trials, espe-
cially in much larger unresectable tumors.
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